Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a dutasteride tablet formulation using cyclodextrin complex, solubilizing polymer, and surfactant achieved similar bioavailability in beagle dogs to that of a commercial capsule.

This study found that a 400-mg dose of oral testosterone with dutasteride increases serum testosterone levels for 8–10 hours in hypogonadal men, with the nanomilled formulation unaffected by food, suggesting a practical twice-daily therapy option.

This study explored using a chitosan oligomer coating for topical delivery of dutasteride-loaded nanostructured lipid carriers, aiming to reduce systemic exposure and cytotoxicity.

This study developed a topical dutasteride-loaded Insitu-emulgel for treating androgenetic alopecia, finding it effectively controls drug release, enhances skin penetration, and may improve patient compliance compared to traditional topical treatments, though further clinical research is underway.

This review examines recent advancements in analytical techniques used to quantify dutasteride, a medication for enlarged prostate, in various biological samples and its commercial forms, emphasizing methods such as HPTLC, GC-MS, and HPLC.

This study found that combining oral testosterone with dutasteride increased testosterone bioavailability in hypogonadal men while suppressing dihydrotestosterone levels over a 28-day period.

This review discusses current treatment options for androgenetic alopecia, noting that most lack robust evidence for efficacy and safety, highlighting the need for more comprehensive studies.

This review examined studies on erectile dysfunction and 5 alpha-reductase inhibitors, concluding that these drugs do not significantly cause erectile dysfunction and emphasizing testosterone's importance over dihydrotestosterone in erectile function.

This review discusses the efficacy and safety of 5-alpha reductase inhibitors for treating androgenetic alopecia, noting concerns about sexual side effects, which are typically uncommon and often resolve over time.

This review examines recent approvals and emerging treatments for androgenetic alopecia, discussing newly approved drugs like Propecia and Rogaine Extra Strength 5%, but without presenting new clinical results.

Dutasteride is more effective than finasteride for hair growth, and pregabalin effectively treats neuropathic pain.

This research focused on formulating finasteride, dutasteride, and minoxidil with cyclodextrins to enhance their solubility and skin penetration for topical use, potentially reducing scalp irritation from current alcohol-based preparations.

This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

This review discusses factors affecting hair health, types of alopecia, and the potential of phytochemicals in managing hair loss but reports no new clinical results; it highlights the need for further studies.

This review provides a detailed overview of the causes, prevalence, pathophysiology, clinical presentation, and treatment of beard alopecia, highlighting conditions such as alopecia areata, pseudofolliculitis barbae, and tinea barbae, and aims to serve as a resource for clinicians handling such cases.

This study in rats found that a new hydroxypropyl-β-cyclodextrin formulation of minoxidil reduced the adverse cardiovascular and proliferative effects seen with traditional minoxidil solutions.

This study developed a validated method to detect prohibited drugs in dietary supplements, finding minoxidil, triaminodil, and finasteride in some samples.

This article examines the public health risks and benefits of pill organizers and cutters, concluding that healthcare professionals should guide their use to prevent potential medication stability and efficacy issues.

In this study, researchers reviewed recent advances in using nanoencapsulation technology to improve the pharmacological treatment of alopecia, suggesting its potential to enhance drug delivery and reduce adverse effects compared to conventional methods.

This review article summarizes the potential role of advanced medical therapies—using genes, cells, and/or tissue engineering—in treating various types of alopecia, by examining clinical research, basic studies, and ongoing trials.

This review discusses the emerging pathophysiological factors and potential new therapies for androgenetic alopecia beyond traditional treatments, but reports no new results.

This study developed two sensitive chromatographic methods for determining finasteride and tamsulosin hydrochloride in pharmaceutical forms, validated against International Conference on Harmonisation guidelines.

This review discusses the topical use of systemic drugs for cutaneous disorders and reports a lack of strong evidence from randomized controlled trials, highlighting the need for larger comparative effectiveness studies.

This study found that the petroleum ether extract of Citrullus colocynthis fruit and an isolated steroidal compound may reduce prostatic hyperplasia in rats induced by testosterone, suggesting potential use in managing androgen-dependent conditions.

Pharmacists play a crucial role in patient care and education.

In this study, researchers found that taking Saw palmetto and Pygeum africana supplements for five days altered the urinary steroid profile in a way that may interfere with the steroidal module of the Athlete Biological Passport.

This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.

This article reviews the genetic and psychological aspects of androgenetic alopecia in men and women, reporting no new clinical findings while emphasizing the broad impact of this hair loss condition.

This review examines the benefits and potential risks of androgen replacement therapy for male hypogonadism but reports no new clinical results; the authors highlight the need for careful risk assessment, especially in older men.

This review discusses cross-sex hormone therapy for managing gender dysphoria in transsexual individuals and reports no new clinical results; it highlights the need for education and culturally sensitive training for healthcare professionals.